Southeastern Medical Center S.C.
Southeastern Medical Center S.C. was paid $2.02M by Medicaid between Jan 2018 and Nov 2024, across 43 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 30% of everything it billed.
33Billing provider infoSOUTHEASTERN MEDICAL CENTER S.C.
HAMMOND, IN 46320
HAMMOND, IN 46320
33aNPI1568589802assigned 03/23/2007
33bProvider typeSpecialist
28Total paid$2.02M
24GClaims207,657
24DCodes billed43
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Specialist providers in Indiana
Rank by total paid#13 of 90
Median peer was paid$98K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 61,679 | $522K | |
| 2019 | 58,499 | $443K | |
| 2020 | 43,428 | $164K | |
| 2021 | 12,273 | $220K | |
| 2022 | 12,190 | $265K | |
| 2023 | 10,750 | $245K | |
| 2024incomplete | 8,838 | $162K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 30% | 18,949 | 11,717 | $599K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 11,754 | 7,286 | $271K |
| 20553 | 11% | 16,123 | 8,097 | $221K | |
| 98925 | 9.4% | 16,948 | 9,683 | $191K | |
| 20610 | 7.4% | 10,161 | 5,174 | $149K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 5.7% | 17,274 | 7,361 | $115K |
| J3490 | Unclassified drugs | 5.1% | 36,464 | 11,797 | $104K |
| 22505 | 4.8% | 6,835 | 3,184 | $97K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.8% | 5,782 | 2,813 | $96K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 1.9% | 24,150 | 12,638 | $38K |
| 99205 | Prolong outpt/office vis | 1.5% | 354 | 264 | $31K |
| 20552 | 1.1% | 1,010 | 861 | $22K |
31 more codes
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 179 | $16K |
| 97760 | <1% | 1,105 | $12K | |
| 20605 | <1% | 1,001 | $11K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,253 | $10K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 653 | $9K |
| 80305 | <1% | 713 | $5K | |
| 73562 | <1% | 283 | $5K | |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | <1% | 81 | $4K |
| 72100 | <1% | 241 | $4K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 4,164 | $3K |
| 97161 | <1% | 43 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 48 | $2K |
| 95913 | <1% | 32 | $2K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 148 | $1K |
| 96002 | <1% | 99 | $593.76 | |
| 73030 | <1% | 43 | $428.23 | |
| 72040 | <1% | 18 | $419.21 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 304 | $405.21 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 12,559 | $334.24 |
| 73600 | <1% | 113 | $264.29 | |
| 73610 | <1% | 20 | $244.24 | |
| 97032 | <1% | 54 | $214.06 | |
| 97014 | <1% | 18 | $177.30 | |
| 94760 | <1% | 214 | $168.79 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 4,129 | $20.30 |
| 97124 | <1% | 19 | $17.58 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 149 | $6.03 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 121 | $4.08 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 16 | $0.00 |
| 97010 | 0% | 13 | $0.00 | |
| L0630 | Lumbar-sacral orthosis, sagittal control, with rigid posterior panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBHAREL, RAJEEV (NETWORK ADMINISTRATOR)